Shrink Nanotechnologies and Corning Enter Licensing Agreement

Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has entered into a licensing agreement with Corning Incorporated (NYSE: GLW).

In exchange for a commercial royalty, Shrink retains an exclusive right to use and sublicense Corning’s patent-pending modular microfluidic system for at least eight years.

The patent-pending Corning modular microfluidic system has been widely published and has generated significant interest from commercial and academic interests since it was first published in 2008 in Lab on a Chip, a high impact academic journal. This system is the world’s first fully functional plug and play modular microfluidics system that truly allows for integrated high PSI connectors, electronics and pumps. This system is capable of being used in numerous commercial research applications where ultra-fast microfluidic design prototyping is desired, in biochemical, biomedical and cell-based drug discovery applications to name a few. Shrink intends to develop this system as a premium microfluidic product offering throughout North America, Europe and Asia.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.